CLINICAL DRUG INVESTIGATION

期刊基本信息

  • 期刊名称:CLINICAL DRUG INVESTIGATION
  • 期刊级别: Science Citation Index Expanded (SCIE) Scopus (CiteScore)
  • 期刊ISSN:1173-2563
  • 期刊EISSN:1179-1918
  • 简称:CLIN DRUG INVEST
  • 影响因子:2.7
  • 实时影响因子:截止2025年5月19日:2.727
  • 五年影响因子:2.5
  • JCI期刊引文指标:0.75
  • h-index:53
  • 2024-2025自引率:0.00%
  • 期刊官方网站:期刊官方网站
  • 期刊投稿网址:https://www.editorialmanager.com/cdia/
  • 是否OA开放访问:No
  • 出版商:Springer International Publishing
  • 出版年份:1989

CLINICAL DRUG INVESTIGATION

Science Citation Index Expanded (SCIE)Scopus (CiteScore)

期刊介绍

Clinical Drug Investigation provides rapid publication of original research covering all phases of clinical drug development and therapeutic use of drugs. The Journal includes:

-Clinical trials, outcomes research, clinical pharmacoeconomic studies and pharmacoepidemiology studies with a strong link to optimum prescribing practice for a drug or group of drugs.
-Clinical pharmacodynamic and clinical pharmacokinetic studies with a strong link to clinical practice.

-Pharmacodynamic and pharmacokinetic studies in healthy volunteers in which significant implications for clinical prescribing are discussed.

-Studies focusing on the application of drug delivery technology in healthcare.

-Short communications and case study reports that meet the above criteria will also be considered.

Additional digital features (including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations) can be published with articles; these are designed to increase the visibility, readership and educational value of the journal’s content. In addition, articles published in Clinical Drug Investigation may be accompanied by plain language summaries to assist readers who have some knowledge, but non in-depth expertise in, the area to understand important medical advances.

期刊语言要求

Language
Presenting your work in a well-structured manuscript and in well-written English gives it its best chance for editors and reviewers to understand it and evaluate it fairly. Many researchers find that getting some independent support helps them present their results in the best possible light.

投稿要求

  • 通讯方式:ADIS INT LTD, 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND, NEW ZEALAND, 1311
  • 涉及的研究方向:医学-药学
  • 出版国家或地区:NEW ZEALAND
  • 出版语言:English
  • 年文章数:67
  • PubMed Central (PMC)链接:http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1173-2563%5BISSN%5D
  • 平均录用比例:较易

CITESCORE

CiteScoreSJRSNIPCiteScore排名
5.400.7710.828
学科分区排名百分位
大类:Medicine
小类:Pharmacology (medical)
Q286 / 275
68%

WOS期刊JCR分区

WOS分区等级:2区

按JIF指标学科分区收录子集JIF分区JIF排名JIF百分位
学科:PHARMACOLOGY & PHARMACYSCIEQ2164/352
53.6%
按JCI指标学科分区收录子集JCI分区JCI排名JCI百分位
学科:PHARMACOLOGY & PHARMACYSCIEQ2141/353
60.2%

期刊分区表预警名单

2025年03月发布的2025版:不在预警名单中

2024年02月发布的2024版:不在预警名单中

2023年01月发布的2023版:不在预警名单中

2021年12月发布的2021版:不在预警名单中

2020年12月发布的2020版:不在预警名单中

中科院2025年3月升级版

点击查看中国科学院期刊分区趋势图
大类学科小类学科Top期刊综述期刊
医学 3区3区3区
PHARMACOLOGY & PHARMACY
药学
1区2区3区

中科院2023年12月旧的升级版

大类学科小类学科Top期刊综述期刊
医学 1区3区1区
PHARMACOLOGY & PHARMACY
药学
3区3区3区

联系我们

QQ:1211130760

微信:iqkan555

微信扫码加好友 微信扫码加好友
QQ扫码加好友 QQ扫码加好友